Elliot Norry
About Elliot Norry
Elliot Norry, M.D., is a seasoned medical professional with extensive experience in internal medicine and gastroenterology, currently serving as the Chief Medical Officer.
Chief Medical Officer Elliot Norry
Elliot Norry, M.D., serves as the Chief Medical Officer. With extensive experience in internal medicine and gastroenterology, Dr. Norry has substantially contributed to various healthcare institutions and organizations. His role as Chief Medical Officer involves overseeing clinical operations, ensuring the best medical practices, and maintaining patient safety standards.
Education and Medical Training of Elliot Norry, M.D.
Dr. Elliot Norry holds a B.A. from Columbia College and earned his M.D. from New York University. He completed a residency in Internal Medicine at Temple University Hospital in Philadelphia, followed by a fellowship in gastroenterology at Thomas Jefferson University Hospital, also in Philadelphia. These academic and training experiences equipped him with a solid foundation in the medical field.
Elliot Norry's Clinical Practice at Abington Memorial Hospital
Dr. Elliot Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania, for 13 years. During this period, he treated a wide range of medical conditions, providing comprehensive care and building trusted patient relationships within the community.
Elliot Norry's Role at GSK: Safety Development Leader
Elliot Norry has been with GSK since 2009, where he has served as the Safety Development Leader. In this role, Dr. Norry managed clinical safety for various pharmaceutical products, including pazopanib for soft tissue sarcoma. His responsibilities included ensuring the efficacy and safety of new drugs during clinical trials.
Chair of Hepatic Safety Panel at GSK: Elliot Norry
In addition to his role as Safety Development Leader, Dr. Elliot Norry served as the Chair of GSK's Hepatic Safety Panel. This position involved overseeing and evaluating the hepatic safety of GSK's product portfolio, ensuring that the liver-related impacts of medications were thoroughly assessed and managed.